Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

PURPOSE: In low–tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has been shown to improve progression-free survival when compared with observation. It is not known whether MR provides superior long-term disease control compared with re-treatment rituximab (RR) administered on an as...

Full description

Saved in:
Bibliographic Details
Main Authors: Kahl, Brad S., Hong, Fangxin, Williams, Michael E., Gascoyne, Randy D., Wagner, Lynne I., Krauss, John C., Habermann, Thomas M., Swinnen, Lode J., Schuster, Stephen J., Peterson, Christopher G., Sborov, Mark D., Martin, S. Eric, Weiss, Matthias, Ehmann, W. Christopher, Horning, Sandra J.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2014
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171355/
https://ncbi.nlm.nih.gov/pubmed/25154829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.5853
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items